Hans Lehrach
Max Planck Institute for Molecular Genetics, Germany
Biography
Hans Lehrach has studied Chemistry in Vienna and obtained his PhD at the Max Planck Institute for Experimental Medicine and the MPI for Biophysical Chemistry in 1974. He then moved on to Harvard University, Boston (1974-1978) and then became Group Leader at EMBL, Heidelberg (1978-1987). He has then joined the Imperial Cancer Research Fund, London (1987-1994) as a Head of the Genome Analysis Department. In 1994, he has returned to Germany to become Director at the MPI for Molecular Genetics. He has founded several biotechnology companies such as Sequana Therapeutics, GPC Biotech, Scienion, Prot@gen, PSF Biotech and Atlas Biolabs. He is the Founder of the Berlin-based company Alacris Theranostics GmbH, specializing in the development of new approaches for personalized medicine for cancer patient diagnosis, treatment and drug stratification. In 2010, he has founded the non-for-profit research institute Dahlem Centre for Genome Research and Medical Systems Biology.
Abstract
Abstract : Virtualized drug development for (truly) personalized drug therapy